Dl-3-n-butylphthalide and Cerebrolysin Treatment in Acute Ischemic Stroke
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The investigators conducted a randomized, double-blind, trial enrolled 60 patients within 12
hours of acute ischemic stroke (AIS) in China. Patients were randomly assigned to receive a
10-day infusion of dl-3-n-butylphthalide (NBP) or cerebrolysin, or placebo. National
Institutes of Health Stroke Scale (NIHSS) and Barthel Index (BI) were used to evaluate the
efficacy in the patients with AIS at 11-day and 21-day after therapy. Adverse events were
also analyzed among the three groups.